Enhertu (fam trastuzumab deruxtecan nxki) is a HER2-directed antibody and topoisomerase inhibitor conjugate. Enhertu (fam trastuzumab deruxtecan nxki) is an antibody-drug conjugate (ADC) composed of three components: 1) a humanized anti-HER2 IgG1 monoclonal antibody (mAb), covalently linked to 2) a topoisomerase inhibitor, via 3) a tetrapeptide-based cleavable linker. Deruxtecan is composed of a protease-cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, which is an exatecan derivative.
---Indications and Usage---
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:
1. Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:
in the metastatic setting, or
in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
2. Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Enhertu (fam trastuzumab deruxtecan nxki) is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commerci...
On August 5, 2022, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki, DS-8201), an IV infusion for the treatment ...
On November 14, Antibody drug conjugate Enhertu (DS-8201, trastuzumab deruxtecan) jointly developed and commercialized by AstraZeneca and Daiichi Sanky...
On December 7, AstraZeneca and Daiichi Sankyo jointly announce the latest DESTINY-Breast03 phase III clinical trial of their jointly developed antibody...
On March 6, Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZen...